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Abstract: Until now only intravenous and oral formulations of 5HT3 receptor antagonists 
have been available. Recently a new formulation of a 5HT3 receptor antagonist, transdermal 
granisetron, has been developed, and approved by the FDA. Three phase I studies to evaluate 
its pharmacokinetic profile have shown that granisetron administered by a transdermal delivery 
system is absorbed by passive diffusion and maximal concentration is reached 48 hours after 
patch application. The patch of 52 cm2, which contains 34.3 mg of granisetron, releases 3.3 mg 
of the drug every day and maintains a stable average plasma concentration of 2.2 ng/mL over 
6 days, similar to levels obtained with 2 mg of oral granisetron, administered every day during the 
same period of time. Two randomized as yet unpublished clinical trials (phase II/III) have been 
conducted to evaluate the antiemetic efficacy of transdermal granisetron in chemotherapy-induced 
nausea and vomiting, in patients receiving moderately and highly emetogenic chemotherapy, 
compared with 2 mg of oral granisetron. More than 800 cancer patients were included in the 
trials. The rate of complete control of acute emesis was 49% for the phase II trial and 60% for 
the phase III trial. Neither trial showed a statistically significant difference between transdermal 
and oral granisetron. The control of delayed emesis was observed in 46% of patients, and there 
were no statistically significant differences between transdermal and oral granisetron. The most 
common adverse effects in both trials were constipation (7%) and headache (1%); there 
were no statistically significant differences between transdermal and oral granisetron. These 
data show that transdermal granisetron is effective and safe in controlling acute emesis induced 
by chemotherapy with both moderate and high emetogenic potential. Efficacy and safety of 
transdermal granisetron are fully comparable with that of oral granisetron. More clinical trials 
using regimens of 2 or 3 drugs, including dexamethasone and/or aprepitant, are needed to 
confirm the place of transdermal granisetron in the control of chemotherapy-induced nausea 
and vomiting.
Keywords: cancer chemotherapy induced nausea and vomiting, selective antagonists of 5HT3 
receptors, granisetron, transdemal delivery system
Introduction
Nausea and vomiting are common symptoms in patients receiving cancer 
chemotherapy. Twenty-five years ago, more than 70% of patients treated with cancer 
chemotherapy experienced nausea and vomiting.1,2 The prevalence and severity of 
chemotherapy-induced nausea and vomiting (CINV) are related to the specific emetic 
potential of chemotherapy (specific drug, dose, and treatment schedule) and to inter-
individual variability. At present, owing to advances in antiemetic treatment over 
recent decades, the incidence of CINV has been reduced to 25%.3–6 It is well known Cancer Management and Research 2010:2 
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that this drastic change in CINV prevalence was due to the 
introduction to clinical practice of selective antagonists of 
5HT3 and NK-1 receptors.
It is important to recognize three different types of CINV 
according to its temporal pattern of onset (acute, delayed, and 
anticipatory), because each type of emesis requires specific 
therapeutic approaches.7,8 The temporal pattern of emesis 
owing to cisplatin administration was the first and more 
widely studied. Without an effective antiemetic treatment, 
almost all patients have nausea and vomiting during the first 
2 hours after the administration of chemotherapy. Often, a 
reduction in the severity of emesis is observed during a period 
between 18 and 24 hours after cisplatin administration, and 
later reappears in the second and third day after administra-
tion. Based on experience of patients treated with cisplatin, 
the definition of different types of CINV , according with its 
temporal pattern of onset, is:7–10
–  Acute CINV occurs during the first 24 hours after 
chemotherapy administration
–  Delayed CINV occurs from at least 24 hours, or later, 
after chemotherapy administration.
–  Anticipatory CINV occurs before drug administration, 
usually when nausea and vomiting have been poorly 
controlled in previous chemotherapy courses. This type 
of CINV is a conditional or learned response. Modern 
antiemetic treatments have reduced the incidence of 
anticipatory CINV . If this type of CINV does appear, the 
therapeutic approach is based mainly on behavioral rather 
than pharmacological interventions.
The combined use of different antiemetic drugs accord-
ing to the temporal pattern of onset and the emetic potential 
of each specific chemotherapy schedule has improved 
drastically the incidence and severity of CINV .3–6
The therapeutic strategies to prevent and control CINV are 
essential to maintain nutritional status, and improve quality of 
life of patients receiving cancer chemotherapy. An adequate 
antiemetic treatment may avoid some clinical complications 
and the frequent need for dose reduction or delayed treat-
ments, which obviously may influence clinical outcomes.
Until recently oral and intravenous formulations of the 
selective 5HT3 receptor antagonists were available, but a new 
formulation of a 5HT3 receptor antagonist (granisetron) by 
transdermal route has now been developed and approved by 
the US Food and Drug Administration (FDA).
Pathophysiology of CINV
Nausea and vomiting are the result of a complex reflex 
mechanism, which involves some neurotransmitters and 
its specific receptors in the central and peripheral nervous 
system.
The emetic process is controlled in the brain by two areas, 
“the vomiting center” and the chemoreceptor trigger zone 
(CTZ). These areas receive and process the different emetic 
stimuli and also generate efferent signals to the respiratory, 
vasomotor, and salivary centers, as well to the cranial nerves 
VIII and X, which results in nausea and vomiting. Wang 
and Borison described in 1950 the central site of emesis 
regulation (vomiting center), located in the nucleus tractus 
solitarii of medulla oblongata.11 It is well known today that 
this area is a rather complex network of neural connections 
rather than an anatomically structured nucleus.6,7,12,13 The CTZ 
is located in the area postrema in the floor of fourth ventricle, 
outside the blood–brain barrier.14–16 For this reason substances 
with emetic potential circulating in blood or cerebrospinal 
fluid can activate directly the CTZ. This mechanism is well 
demonstrated in vomiting related to administration of opioids 
or dopaminergic drugs.17,18
The afferent pathway of the vagus nerve, activated by dif-
ferent gastrointestinal stimuli, is projected onto the nucleus 
tractus solitarius (vomiting center) and the area postrema 
(CTZ), provoking the efferent emetic reflex. Dopamine, 
opioids, histamine, acetylcholine, substance P, and serotonin 
are the main neurotransmitters involved in the stimulation 
of the emetic reflex by activating its specific receptors in 
both the central nervous system and in peripheral nerve 
fibers. Therefore, the pharmacologic treatment of nausea and 
vomiting is mainly aimed at blocking the specific receptors 
of some of these neurotransmitters.
Chemotherapy administration causes the release of 
mediators, mainly serotonin, through stimulation of the 
enterochromaffin cells of intestinal mucosa. These mediators 
bind to the specific receptors in vagal primary afferent 
neurons. The projection of vagal stimulus in the central 
nervous system (vomiting center and CTZ) triggers the 
emesis reflex. The most important neurotransmitters in 
CINV are serotonin, dopamine, and substance P, which bind 
to 5HT3, dopamine-2, and NK-1 receptors, respectively.19,20 
Another way of emesis activation may be the direct 
stimulation of CTZ by metabolites of chemotherapy or 
intestinal peptides circulating in the blood. This mechanism 
is considered possible and reasonable, but has still not fully 
demonstrated.7
It is well accepted that learned or conditional responses 
of the brain are generated in the limbic region of cerebral 
cortex. This brain area is probably responsible for 
anticipatory CINV .8Cancer Management and Research 2010:2 
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The cancer chemotherapy can be classified according 
their specific level of emetogenic risk, from a low level (less 
than 10%) to a high level of risk (up to 90%) (Table 1).7
Brief review of antiemetic 
agents and evidence-based 
recommendations
As mentioned above, the efficacy of antiemetic agents is 
based on their antagonist action over specific receptors of 
neurotransmitters involved in the vomiting reflex. These 
agents can be classified according to the balance between 
efficacy and side effects, as low or high therapeutic index.
Metoclopramide, butyrophenones, phenotiazines, can-
nabinoids, and olanzapine are considered agents of low 
therapeutic index. The selective 5HT3 antagonists, or NK-1 
receptors and dexamethasone are considered agents of high 
therapeutic index.
Olanzapine antagonizes the 5HT3 and D2 receptors. 
In some phase 2 clinical trials olanzapine showed efficacy 
in preventing acute and delayed CINV , but no phase 3 trials 
have yet compared olanzapine with other antiemetic agents 
alone or in combination.21,22
Benzodiazepines have a very low antiemetic action; how-
ever their action reducing the anxiety can help in anticipatory 
emesis or as complementary treatment with other antiemetic 
agents.23,24
Metoclopramide at the usual therapeutic doses, 
butyrophenones, phenotiazines, and olanzapine have an 
antagonist action over dopamine receptors (D2). At present 
these agents are not widely used because they have a moder-
ate antiemetic capacity and a high prevalence of side effects. 
Metoclopramide administered in high doses acquires the 
capacity to block 5HT3 receptors, which improves its efficacy 
but it has frequent side effects.7,25
The synthetic cannabinoids nabilone and dronabinol 
have antiemetic efficacy during chemotherapy with low or 
moderate vomiting risk. The frequent occurrence of dyspho-
ria and postural hypotension are side effects that limit their 
habitual use.26
Although the antiemetic mechanism of corticosteroids is 
not well known, their efficacy in vomiting control during che-
motherapy with low emesis risk has been widely studied and 
demonstrated. Most clinical experience of effective vomiting 
control, efficacy in delayed and acute emesis has been reported 
with methylprednisolone and dexamethasone. The combined 
use of corticosteroids with other antiemetic agents, especially 
with 5HT3 receptor antagonists, is highly efficacious and is 
superior to that when administering of this drug alone.27–30
It is well recognized that selective 5HT3 receptor antago-
nists (ondansetron, granisetron, dolasetron, tropisetron, 
palonosetron) are the most efficacious antiemetic agents 
in CINV. Ways of improving tolerance to chemotherapy 
Table  emesis risk level of antineoplastic drugs
Level  (0%)  Level  (0%–0%) Level  (%–90%) Level 4 (90%)
Bleomicin Bortezimib Carboplatin Carmustine
Busulfan Cetuximab Cyclophoshamide Cisplatin
vinbalstine Cytarabine (1.5 g/m2) Cyclophosphamide
vinorelbine (100 mg/m2) Cytarabine (1.5 g/m2)
Fludrabine Docetaxel Daunorubicin Dacarbazine
Cladribine etoposide Doxorubicin Mechlorethamine
Bevacizumab Flouracil epirubicin Streptozocin
Gemcitabine idarubicin
ixabepilone ifosfamide
Lapatinib irinotecan
Methotrexate Oxaliplatin
Mitomicyn
Mitoxantrone
Paclitaxel
Pemetrexed
Temsirolimus
Topotecan
TastuzumabCancer Management and Research 2010:2 4
Tuca Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
using 5HT3 receptors have seen drastic changes since their 
introduction to clinical practice during the last decade of the 
20th century. A large number of controlled clinical trials and 
meta-analyses have confirmed the superiority of selective 
5HT3 receptor antagonists over other antiemetic agents, and 
demonstrated no clinically relevant differences between 
drugs of this therapeutic group.31–33 Clinical trials confirmed 
fully the efficacy of selective 5HT3 receptor antagonists in 
prevention and control of acute emesis, but they showed only 
a modest action in control of delayed emesis.34
Palonosetron is a new 5HT3 receptor antagonist, recently 
introduced into clinical practice, which shows a longer 
half-life (40 hours) and greater affinity for 5HT3 receptors 
than other drugs of this group.35,36 Clinical trials comparing 
palonosetron with ondansetron or dolasetron, in moderately 
emetogenic chemotherapy, showed a statistically significant 
improvement in complete antiemetic response rate, for acute 
and delayed phase emesis in those patients who received 
palonosetron.37,38 Clinical trials comparing palonosetron 
and ondansetron in highly emetogenic chemotherapy 
did not show differences in rate of complete antiemetic 
response for the acute phase. However, some trends of 
superiority were observed in secondary end-points, such 
as a significantly longer time until the first emetic episode, 
and also showed a statistically significant improvement for 
the delayed phase in a subgroup of  patients who received 
concomitant treatment with dexamethasone.39,40 The efficacy 
of palonosetron in patients who have not responded to 
previous antiemetic treatment, in moderately or highly 
emetogenic chemotherapy, has been studied in a phase II 
clinical trial, according to different age subgroups (elderly 
and nonelderly patients). This clinical trial showed a high, 
complete antiemetic response rate with a single dose of 
palonosetron, irrespective of patient age.41 A recent, large 
phase III clinical trial which included 1114 patients receiving 
highly emetogenic chemotherapy, showed that palonosetron 
and dexamethasone are noninferior to granisetron and 
dexamethasone in antiemetic control of acute phase emesis, 
and better than granisetron and dexamethasone in the 
delayed phase.42
Aprepitant was the first antagonist of the NK-1 receptor 
approved by the FDA and was introduced into clinical prac-
tice in 2003. In controlled clinical trials with chemotherapy of 
moderate or high emesis potential, combined treatment with 
aprepitant, 5HT3 receptor antagonists, and dexamethasone 
showed more efficacy than 5HT3 receptor antagonists and 
dexamethasone alone. These clinical trials also demonstrated 
that the use of aprepitant and dexamethasone between the 
second and fifth day was superior to dexamethasone alone 
for control of delayed emesis.4,43–47 An open-label, phase II 
study (n = 58) which evaluated the efficacy and safety of 
the triple therapy with palonosetron, dexamethasone, and 
aprepitant for prophylaxis of CINV in highly and mod-
erately emetogenic chemotherapy, showed a complete 
antiemetic response in more than 87% in acute phase and 
more than 77% in delayed phase emesis.48 Phase III clinical 
trials are needed for confirm the place of palonosetron 
in such a 3-drug regimen according to its efficacy 
and safety compared with the older 5HT3 antagonist.
The general recommendations for managing CINV 
according to the majority of scientific cancer associations, 
from the best available clinical evidence (level I, randomized 
clinical trials) are:6,34,49
–  Chemotherapy with low emetic risk: Use dexamethasone 
if it is considered appropriate.
–  Chemotherapy with moderate emetic risk: Use a 2-drug 
regimen combining a 5HT3 receptor antagonist and 
dexamethasone to prevent acute emesis and either one 
of these drugs to prevent delayed emesis.
–  Chemotherapy with high emetic risk: Use a 3-drug 
regimen combining a 5HT3 receptor antagonist, 
dexamethasone, and aprepitant to prevent acute emesis, 
and a 2-drug regimen combining aprepitant and dexa-
methasone for delayed emesis.
Transdermal granisetron
Granisetron is chemically designated as 1-methyl-N-
[(1R,3r,5S)-9-azabicyclo [3.3.1] non-3-yl] -1H-indazole 
3-carboxamide. Its molecular weight is 348.9 (312.4 free 
base) and its empirical formula is C18H24N4O⋅HCl.
Granisetron is a selective of 5HT3 receptor antagonist 
without relevant affinity to other serotonin receptors. This 
agent does not show affinity for α-adrenergic, β-adrenergic, 
dopamine, histamine, or opioid receptors. The antiemetic 
activity of granisetron, as with other selective 5HT3 
receptor antagonists, is centered on blockage of specific 
receptors in terminal vagal fibers and in the CTZ. The most 
common adverse effects, similar to those other drugs of 
this pharmacologic group, are headache, constipation, and 
asthenia.
Until recently granisetron has been available only 
for intravenous and oral administration. A large number 
of clinical trials have demonstrated the high efficacy 
of granisetron for control of CINV, with no relevant 
differences from the other classic selective 5HT3 receptor 
antagonists.Cancer Management and Research 2010:2 
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Recently, a transdermal patch of granisetron has 
been developed, which has been approved by the FDA 
for prevention and control of CINV .
Pharmacokinetics of transdermal 
granisetron
Absorption and skin tolerability
Three phase I studies have evaluated the pharmacokinetic 
profile and skin tolerability of the granisetron transdermal 
delivery system. The first phase I study was conducted 
in Germany in 2003. Twelve healthy subjects between 
18 and 40 years of age were enrolled. Two patches were 
applied to all patients, a granisetron transdermal patch 
and a placebo patch, and were removed after 6 days of 
treatment (120 hours). The granisetron patch had a total 
area of 15 cm2 with a granisetron dose of 660 µg/cm2. The 
plasma levels of granisetron were quantified every 24 hours 
during 7 days. Physical examination, routine laboratory 
determinations, electrocardiogram, dermal tolerability, and 
patch adhesiveness were also recorded. Pharmacokinetic 
parameters were quantified in 11 subjects. The maximum 
plasma concentration (Cmax) obtained in any subject was 
5.2 ng/mL. The mean maximum concentration values were 
1.5 ng/mL and the median peak time of concentration (tmax) 
was 48 hours. The steady-state plasma concentration was 
reached between 24 and 30 hours after patch application. 
The plasma concentrations were stable during more than 
5 days of treatment. The mean area-under-the-curve (AUC) 
concentration was 114 ng⋅h/mL. The placebo patch was 
applied only to compare adhesiveness and dermal tolerability 
with those of the granisetron patch. A few subjects in both 
groups presented erythema and a small area of patch detach-
ment was observed in fewer than 10% of cases.50
A second phase I pharmacokinetic study in conducted 
2005 evaluated 3 different doses of granisetron transdermal 
patch and compared them with 2 mg of oral granisetron dur-
ing 5 days of treatment. Twelve healthy volunteers between 
18 and 45 years were enrolled. The subjects were random-
ized in 4 treatment groups: once-daily dose of 2 mg oral 
granisetron during 5 days and patches of 52 cm2, 33 cm2, 
15 cm2, containing 34.3 mg, 21.8, and 9.9 mg of granis-
etron respectively, applied during 5 days. All 12 subjects 
completed the study. The mean of Cmax in the oral granis-
etron arm was 5.25 and 5.50 ng/mL in the first and fifth day 
respectively. The average plasma concentration (Cavg) was 
2.14 and 2.6 ng/mL in the oral granisetron arm in the first 
and fifth day, respectively. The average plasma concentra-
tion (Cavg) for granisetron patches of 15, 33, and 52 cm2 was 
0.68, 1.24, and 2.23 ng/mL, respectively. The AUC(0→∞) 
with 52 cm2 granisetron patch was 420 ng⋅h/mL. Tmax in the 
3 different dosages of transdermal granisetron was achieved 
at 48 hours and the plasma levels were stable during the 5 days 
of treatment. Skin tolerability was assessed as acceptable for 
all subjects in the three different patch doses. Plasma protein 
binding was approximately 65%. Granisetron was distributed 
freely between plasma and red blood cells. The stratified 
analysis showed no differences in granisetron clearance 
owing to age, gender, weight, or renal function.51,52
The third study was a phase I study, double-blind, random-
ized, and placebo-controlled to evaluate skin irritation and the 
sensitization potential related with granisetron administered 
by a transdermal delivery system. Two hundred and twelve 
subjects aged between 19 and 63 years were enrolled in this 
study. This trial compared a granisetron patch of 52 cm2 and a 
placebo patch, both applied for different periods of exposure 
(30 minutes and 24, 48, and 72 hours, and 8, 15, and 22 days). 
To assess dermal tolerability a dermal response grading scale 
was used, divided into 5 points: 0, no reaction; 1, slight ery-
thema; 2, moderate erythema; 3, severe erythema or erythema 
with edema; 4, erythema with vesicles or erosion. Patch 
adhesion was also evaluated systematically every 48 hours 
during the time of transdermal treatment. Slight or moderate 
skin reactions, 8 days after patch application, were higher for 
the placebo group (22.4%) than the transdermal granisetron 
group (13.5%). Allergic contact reaction was observed in only 
1 subject of the transdermal granisetron group (0.5%). No 
sensitization reactions were observed with the placebo patch. 
Adherence to greater than 90% of patch surface, 8 days after 
patch application, was observed in 59% of granisetron group 
and in 69% of placebo group. Pharmacokinetic parameters 
were quantified in 24 granisetron subjects. Mean Cmax was 
4.0 ng/mL for women and 2.16 ng/mL for men. Mean Cavg 
was 1.53 for men and 3.2 ng/mL for women.54
In summary, the main overall conclusions of these phar-
macokinetics studies are: granisetron administered by the 
transdermal delivery system was absorbed by passive diffu-
sion; maximal concentration was reached 48 hours after patch 
application; plasma levels were stable for at least 6 days; 
a patch of 52 cm2 delivered 3.3 mg/day of granisetron, and 
maintained a Cavg of 2.2 ng/mL over 6 days, similar to that 
obtained with 2 mg of oral granisetron administered every 
day during the same period of time; no dose adjustment was 
needed owing to age or renal function (Table 2); and when 
the patch was removed, after 6 days of treatment, the plasma 
concentration decreased slowly over approximately 72 hours 
until it became undetectable (Figure 1).50–54Cancer Management and Research 2010:2 
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Metabolism and excretion
Metabolism of granisetron involves N-demethylation and 
aromatic ring oxidation, followed by conjugation with 
glucoronide sulphate. In vitro studies have shown that 
ketoconazol inhibits the metabolism of granisetron, which 
suggests a metabolism mediated partly by cytochrome 
P450 3A. Animal experimentation studies suggest that 
some of the metabolites have antagonist activity over 5HT3 
receptors. Granisetron clearance is predominantly hepatic. 
Less than 20% of dose administered intravenously is excreted 
unchanged in urine. The rest of the dose administered is 
excreted 49% by the urine and 34% by the feces as metabo-
lites, mainly 7-hydroxi-granisetron. For this reason dose 
adjustment in renal failure is considered unnecessary.54,55
All these data correspond to previous experimental 
studies of parenteral or oral granisetron. Although there are 
no specific data on the metabolism of this drug administered 
transdermally, it is reasonable to believe that metabolic 
pathways do not differ between different routes of admin-
istration.
Clinical studies with transdermal 
granisetron
Two clinical studies have evaluated the efficacy and safety 
of the transdermal granisetron patch in CINV .
The first was a double-blind, double-dummy, randomized, 
multicenter, phase II study, comparing efficacy, safety, and 
tolerability of the granisetron patch and oral granisetron in 
CINV , following a single-day administration of moderately 
emetogenic chemotherapy. The study was conducted at 
21 centers in Germany and included 210 cancer patients with 
a randomization ratio of 1:1. The granisetron patch group 
was treated 24 hours after chemotherapy administration, 
with a 52 cm2 patch containing 34.3 mg of drug, followed 
by a placebo capsule. The control group was treated with a 
placebo patch followed by a 2 mg granisetron capsule. Rescue 
antiemetic medications, such as dexamethasone 8 mg or an 
extra dose of granisetron, were allowed if the patients had 
severe nausea–vomiting. The number of emetic episodes 
and the severity of nausea, assessed by means a 4-point scale 
(no nausea, mild, moderate, and severe nausea), were recorded 
daily. The patients also recorded the use of rescue medica-
tions, and their satisfaction related specifically to nausea 
and vomiting control, using a 100 mm visual analogue scale 
(VAS). The primary endpoint of this study was to determine 
the proportion of patients achieving total control of CINV 
(no emetic episode, no nausea, and no rescue medication) or 
a complete control of CINV (no emetic episodes, no more 
than mild nausea, and no use of rescue medication). The 
secondary endpoints were the proportion of patients achieving 
a complete response or complete control during acute phase 
(first 24 hours) and delayed phase, and also during the overall 
trial period (120 hours). Total control and complete control 
were achieved by 43.7% and 48.3% of patients, respectively, 
during acute phase in the transdermal granisteron arm, 
compared with 52.4% and 59.5% in the oral granisetron 
arm (not statistically significant). Total control and complete 
control were achieved by 32.2% and 42.5% of patients, 
respectively, during delayed phase in the granisteron patch 
arm compared with 29.8% and 40.5% in the oral granisetron 
arm (not statistically significant). There were no statistically 
significant differences in severity of nausea–vomiting, num-
ber of emetic episodes, and patient satisfaction between the 
two trial groups (Table 3). Only 5 patients showed a patch 
adhesion failure, 1 in the granistetron patch group and 4 in 
control group. Side adverse events (SAE) were experienced by 
30.7% of granisetron patch patients compared with 18.8% of 
oral granisetron patients. However, the proportion of adverse 
events that were considered related to trial treatment was 
higher in the control group than in the transdermal granisetron 
group (9.4% versus 4.5%). The most common SAE recorded 
was headache (3.4% in granisetron patch group, 4.7% in 
control group). Treatment-related deaths or severe SAE were 
not observed, and the overall evaluation of SAE did not show 
any relevant differences between both groups.54–57
The second study was a randomized, active control, 
double-blind, double-dummy, parallel-group, phase III, 
multicenter, multinational trial to assess efficacy, tolerability, 
and safety of transdermal granisetron compared with oral 
granisetron in CINV associated with moderately and high 
multiday chemotherapy. A total of 641 cancer patients were 
included from 60 centers in 9 countries. The transdermal 
Table  Pharmacokinetics parameters of oral and transdermal 
granisetron49,50,61
Mean Granisetron  mg oral 
daily
Granisetron 
patch  cm
Day  Day 
Cmax ng/mL 5.2 5.5 4.0–2.2
tmax (hours) 1.5 2.0 48
Cavg (ng/mL) 2.14 2.6 2.23
AUC (0→∞) ng⋅h/mL 65 98 420
t½ (hours) 6.4 7.9 35.9
Abbreviations: Cmax, maximal mean concentration; tmax, peak of maximal concentration; 
Cavg, average concentration;   AUC, area under the curve concentration; t½, half-life.Cancer Management and Research 2010:2 
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granisetron group included 318 patients, who were treated 
with a 52 cm2 patch containing 34.3 mg of drug, applied 
24 to 48 hours before chemotherapy (which was removed on 
the seventh day) and associated with a placebo capsule 
administered 1 hour before chemotherapy every day and only 
during the days of chemotherapy administration. The control 
group included 323 patients, who were treated with a placebo 
patch, applied 24 to 48 hours before start of chemotherapy 
(removed on the seventh day) with 2 mg granisetron capsule 
1 hour prior chemotherapy every day during the days of 
chemotherapy. Unlike the previous phase III clinical trial, 
the concomitant use of corticosteroids was permitted as a 
part of chemotherapy regimen. More than 40% of patients 
in both treatment groups had metastatic disease, 30% of 
whom had been treated previously with chemotherapy 
and 20% of whom a had history of prior radiotherapy. 
More than 70% of patients received a 3-day chemotherapy 
regimen, which included cisplatin, oxaliplatin, carboplatin, 
or topotecan. It was considered that most of patients had 
regimens of combined chemotherapy with high emetogenic 
risk. The primary endpoint was to determine the proportion 
of patients achieving complete control of emesis defined as 
no emetic episodes, no more than mild nausea, and no use 
of rescue medication. The complete control of emesis in 
acute phase was achieved in 60.2% of patients treated with 
transdermal granisetron compared with 64.8% of those 
treated with oral granisetron; there were no statistically 
significant differences (Table 3). A stratified analysis was 
done according to sex, chemotherapy regimen (cisplatin 
and no cisplatin, use or no use of corticosteroids), duration 
of chemotherapy, and prior chemotherapy treatments. 
There were no statistically significant differences between 
these stratified groups in the rate of complete control of 
emesis in the acute phase. The use of rescue medication 
differed according to the duration of chemotherapy treatment. 
In chemotherapy regimens of 4 or 5 days, the use of rescue 
medication was higher with transdermal granisteron than 
with oral granisetron. In patients treated with chemotherapy 
regimens of 3 days the use of rescue medication did not differ 
between transdermal and oral granisetron groups. There were 
no significant differences between both groups in patient 
global satisfaction assessed by means VAS. Constipation 
was the more common SAE, occurring in 6.6% of patients 
treated with the granisetron patch compared with to 3.1% 
in the oral granisetron group. Headache related to granisetron 
use was observed in 0.3% of transdermal patients versus 
2.5% of oral patients. Asthenia, dyspepsia, and abdominal 
pain were observed in less to 3% of patients in both groups. 
Serious SAEs potentially related to granisetron were reported 
in 5 cases (0.8%), 1 patient in the transdermal group (severe 
constipation) and in 4 patients in the oral group (3 with QTc 
prolongation and 1 with megacolon). Fifteen patients (2.3%) 
died during the study period, 7 in transdermal group and 8 in 
oral group. Only one of these deaths, caused by megacolon 
in the oral group, was considered to be potentially related 
to granisetron. Twelve patients (1.9%) withdrew from the 
study treatment owing to SAEs, 6 in each trial arm. Two-
thirds of patients showed a patch adhesion of greater than 
90% of its surface during the trial period.54,58
Discussion
The pharmacokinetic parameters of granisetron transdermal 
delivery system have been recently published,59 and data on 
phase II–III clinical trials are still unpublished. The informa-
tion included herein on clinical trials is derived from scientific 
documents provided by the pharmaceutical company that has 
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developed this new route of administration of granisetron, 
most of which are available on the Internet.54,56–58
The pharmaconkinetic studies in healthy volunteers dem-
onstrated that plasma concentrations of granisetron delivered 
by the transdermal system were similar to those obtained 
with oral granisetron. Cavg levels were greater the 2 ng/mL 
and were stable over more than 6 days in both treatments 
(oral administration every day or continuous transdermal 
delivery). Tmax was reached later with the granisetron patch 
(48 hours) compared with oral granisetron (1.5 hours on 
first day). Despite this slow absorption by passive diffusion, 
a therapeutic level was reached after 24 hours of patch appli-
cation. In a third pharmacokinetic study, the Cmax obtained in 
women was higher than that observed in men. This difference 
did not affect Cavg, which reached the therapeutic level in both 
genders for more than 6 days.55 The plasma concentration 
of granisetron decreases 24 to 48 hours after patch removal, 
and becomes undetectable in a few days. According to this 
pharmacokinetic profile it is possible to maintain a stable 
plasma concentration at therapeutic levels during 5 days if 
the patch is applied 24 hours before the start of chemotherapy 
and is removed on sixth day.
According to available literature, the usual rate of emesis 
control in chemotherapy with moderate or high emetic 
potential using 5-HT3 receptor antagonists is between 
40% and 86%.59–64 The higher rates of emesis control 
in moderately emetogenic chemotherapy are achieved 
with 2-drug regimens combining 5-HT3 antagonists and 
dexamethasone (75% in acute emesis and 92% in delayed 
emesis).6,59,60 In highly emetogenic chemotherapy, the higher 
rates of emesis control are achieved with 3-drug regimens 
combining 5-HT3 antagonists, dexamethasone, and aprepitant 
(83% to 93% in acute emesis and 79% to 76% in delayed 
emesis).6,27,28,64,68–70 The clinical trials that included specifi-
cally granisetron combined with dexamethasone reported a 
rate of complete emesis control in 60% and 86% of patients, 
higher than the 70% with intravenous granisetron,61 and 60% 
to 86% with oral granisetron.62–64 A recent phase III clinical 
trial comparing palonosetron plus dexamethasone with intra-
venous granisetron plus dexamethasone in highly emetogenic 
chemotherapy reported a 73.3% complete response with 
granisetron plus dexamethasone.42
It is not possible compare these findings (2- or 3-drug 
regimens) with the results of transdermal granisetron trials, 
because only granisetron monotherapy was used.
We need to review older clinical trials evaluating 
the efficacy of 5-HT3 antagonists administered alone 
without the use of corticosteroids for control of CINV. 
Several literature reviews on the use of 5-HT3 receptor 
antagonists used in monotherapy, for control of CINV in 
chemotherapy with moderate emetic potential, have reported 
an emetic control rate of 40% to 60%.6,59,60,66 Some older 
phase II/III clinical trials, which evaluated the efficacy 
of granisetron alone, without corticosteroids, in highly 
emetogenic chemotherapy, reported a complete control of 
emesis (no emetic episodes, no more than mild nausea, no 
rescue medication) in 52% to 49% of patients, and a complete 
response (no emetic episodes, no nausea, no medication 
rescue) in 36% to 32% of patients.65,66
In the first phase II clinical trial comparing transdermal 
granisetron patch with oral granisetron, complete antiemetic 
control in acute phase was achieved in 48.3% and 59.5% of 
patients, respectively.54,56,57 The control of CINV in half the 
patients treated with transdermal granisetron is comparable 
Table  Rate of acute emesis control and related-treatment side adverse effects in controlled clinical trials56,59,60
    Transdermal granisetron Oral granisetron
Phase ii (N = 210) Complete controla 48.3% 59.5%
Related-treatment SAe 4.5% 9.4%
  Constipation nr nr
  Headache 3.4% 4.7%
Phase iii (N = 641) Complete control 60.2% 64.8%
Related-treatment SAe 7.9% 5.6%
  Constipation 6.6% 3.1%
  Headache 0.3% 2.5%
Note: No statistically significant differences in all items in both trials.
aComplete control: no more than mild nausea, no vomiting, no rescue medication.
Abbreviations: nr, not reported in available documentation; SAe, side adverse effects.Cancer Management and Research 2010:2 9
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with previous data on oral granisetron alone (52%).66 
This rate of emesis control is also comparable with that 
of other selective 5-HT3 antagonists used in monotherapy, 
(40% to 60%),59,60,66 taking into account that there are no 
relevant differences in clinical efficacy between classic 5-HT3 
antagonists assessed by meta-analyses.32,33,67
A large phase III clinical trial on transdermal granisetron 
has been conducted.58 The main differences between this study 
and previous phase II clinical trials57 were the inclusion of 
patients receiving high emetogenic potential chemotherapy, 
and the possibility of adding corticosteroids as part of the 
chemotherapy regimen. A complete control of emesis in the 
acute phase was achieved in 60.2% of patients treated with 
transdermal granisetron, although there were no statistically 
significant differences compared with the control group 
treated with oral granisetron. Despite the inclusion of patients 
receiving high emetogenic chemotherapy, the rate of emesis 
control in this study is higher than reported in a previous 
phase II clinical trial in moderately emetogenic chemotherapy 
(49.4%). The concomitant use of corticosteroids as part of 
chemotherapy in some patients could be the reason for an 
overall improvement of emesis control. However, a stratified 
analysis comparing patients who received or did not receive 
corticosteroids in both arms of the trial did not show any 
statistically significant differences.
As expected, according to the pharmacological profile 
of granisetron, and other 5HT3 receptor antagonists, the 
antiemetic efficacy which was assessed in these clinical 
trials57,58 was mainly focused on acute vomiting. The emetic 
control in delayed phase was comparable in both arms of the 
two trials, 46.0% for granisetron patch versus 46.4% for oral 
granisetron (no statistically significant differences). A relevant 
finding in a phase III clinical trial is the need for more rescue 
medication for transdermal granisetron patients in chemother-
apy regimens longer than 3 days. The pharmacokinetic data 
show a slight decrease in plasma concentration of granisetron 
from the fourth day of patch application, despite maintaining 
a mean concentration at therapeutic levels. A higher peak 
of maximal plasma concentration, by oral administration of 
granisetron every 24 hours, may be the reason for a lower need 
of rescue medication in chemotherapies longer than 3 days.
Constipation and headache are the most common SAEs 
for 5HT3 receptor antagonists reported in literature, and appear 
in around 10% of patients.73 Constipation was observed in 
less of 7% of patients and headache in less of 1% of patients 
treated with transdermal granisteron (not statistically 
significant compared with oral granisetron control group), 
and fully comparable with reported SAE rates.
Skin adhesion of the patch is very important to assure an 
optimal absorption of drug by passive diffusion. A rate of skin 
adhesion of greater than 90% of patch surface was found in 
most of patients, a fact confirmed also in the pharmacokinetic 
studies by stable mean plasma concentrations during more than 
6 days. Patient satisfaction with overall control of emesis was 
assessed using a VAS. There were no statistically significant 
differences in patient satisfaction between transdermal and oral 
granisetron for emesis control. Opinion about the comfort of 
drug administered by patch and preferences of patients were 
not assessed in these studies because the trials were double 
dummy and the patch was applied in all patients.
The management of nausea and vomiting induced by 
radiotherapy includes measures to modify risk factors and 
prophylactic antiemetic medication in those treatments with 
high emetic potential. The usual antiemetic treatments used 
for this indication are the dopamine antagonists, antihis-
tamines, anticholinergics, and 5HT3 antagonists. A recent 
literature review confirmed that 5HT3 antagonists, with or 
without corticosteroids, achieved better emesis control than 
other antiemetic drugs.71 Transdermal granisetron may be an 
effective and comfortable option to treat the emesis induced 
by radiotherapy. It would be reasonable and interesting 
to conduct controlled clinical trials comparing oral 5HT3 
antagonists and transdermal granisetron with or without 
corticosteroids in radiation therapy with high emetic risk.
The symptomatic treatment of inoperable malignant bowel 
obstruction is based on rational use of analgesia, corticoste-
roids, and antiemetic and antisecretory drugs. Two recent 
systematic literature reviews, published in 2004 and 2007, rec-
ommended the use of octreotide, a synthetic analog of soma-
tostatin, in patients with inoperable bowel obstruction.74,75 The 
antisecretory effect of octreotide was higher than that of other 
anticholinergic drugs (hyoscine). According to clinical trial 
data, the combination of octreotide plus dopamine antagonist 
significantly increased the rate of nausea and vomiting control 
compared with hyoscine plus dopamine antagonist. The butyr-
ophenones and phenotiazines, haloperidol or chlorpromazine, 
have been the dopamine antagonists more frequently used. 
Most of authors do not recommend the use of metoclopramide, 
because its prokinetic effect may paradoxically increase colic 
pain. Efficacy of granisetron in control of nausea and vomiting 
owing to inoperable malignant bowel obstruction in advanced 
cancer patients has been recently reported.72 This phase II 
clinical trial showed excellent antiemetic control when using 
intravenous granisetron plus dexamethasone in more than 
85% of patients with inoperable malignant bowel obstruc-
tion and previous inadequate control with antiemetic drugs.   Cancer Management and Research 2010:2 0
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The use of octreotide was no allowed in this trial because 
it was a phase II study addressed to demonstrate efficacy 
of granisetron in a new indication. Phase III clinical trials 
are needed to compare granisetron and standard dopamine 
antagonists, combined with dexamtehasone and octreotide 
in both groups, to confirm the clinical efficacy of 5HT3 
antagonists in symptomatic control of inoperable bowel 
obstruction. It would also be very interesting to explore by 
means of controlled clinical trials the antiemetic efficacy of 
transdermal granisetron associated with corticosteroids and 
octreotide in this severe complication.
The comfort of patients is highly important and must be 
considered. Although patient satisfaction, mainly in relation to 
emesis control, with transdermal administration has been shown 
in clinical studies to be similar to that with oral administration. 
The transdermal route may bring more comfort to the patient. 
The patch is simple to apply and is maintained throughout 
chemotherapy without skin problems in most patients. For these 
reasons transdermal treatment may reassure patients because 
they do not need to remember to take a pill. The substitution 
of intravenous administration of 5HT3 antagonists with 
transdermal administration can avoid one of the many venous 
manipulations necessary in chemotherapy, especially important 
in multiday treatments. In patients with swallowing disorders 
(such as, dysphagia, mucositis, structural changes in the oral 
cavity, vomiting) the transdermal delivery of granisetron may be 
easier and less invasive than intravenous administration. Future 
studies on the granisetron patch should include the assessment 
of quality of life using validated scales, and qualitative 
exploration of patient satisfaction or preference.
The overall conclusion to be drawn from the the data 
reviewed is that transdermal granisetron is effective and safe 
in controlling acute emesis induced by chemotherapy with 
moderate and high emetogenic potential, and its efficacy and 
safety are fully comparable with those of oral granisetron. 
However, more phase III clinical trials are needed to confirm 
the place granisetron transdermal delivery systems for the 
control of CINV . In order to improve our knowledge about 
transdermal granisetron these proposed controlled clinical 
trials must be focused on the following areas:
–  Comparison of granisetron transdermal delivery system 
with other selective 5HT3 receptor antagonists, including 
palonosetron, in 2- or 3-drug antiemetic regimens (with 
dexamethasone or with dexamethasone plus aprepitant), 
according to the different levels of chemotherapy emetic 
risk, for the control of acute and delayed CINV .
–  Comparison of granisetron transdermal delivery system 
with other selective of 5HT3 receptor antagonists, in 
radiotherapy-induced nausea–vomiting or in symptomatic 
control of inoperable malignant bowel obstruction.
–  Quality of life (validated tools), and patient satisfaction 
and/or preference related specifically to transdermal 
administration compared with oral or intravenous of 
5HT3 antagonists.
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